Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|VRTX||Vertex Pharmaceuticals, Inc.||0.58%||288.98||1.9%||$508.85m|
|GILD||Gilead Sciences, Inc.||-0.03%||62.34||1.0%||$477.30m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.20%||596.56||2.6%||$452.80m|
|SNSS||Sunesis Pharmaceuticals, Inc.||3.00%||3.78||0.7%||$264.24m|
|CRSP||CRISPR Therapeutics AG||10.68%||70.60||0.6%||$192.52m|
|BMRN||BioMarin Pharmaceutical, Inc.||1.62%||86.36||4.2%||$117.47m|
|EXAS||EXACT Sciences Corp.||7.95%||44.40||17.7%||$102.51m|
|NTLA||Intellia Therapeutics, Inc.||16.98%||63.18||2.2%||$99.79m|
|AXSM||Axsome Therapeutics, Inc.||1.40%||41.21||1.8%||$99.33m|
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firmâ€™s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.